Huperzine A for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials
Key Finding
Huperzine A significantly improved cognition and daily function in Alzheimer's patients across 20 RCTs, comparable to prescription drugs.
Plain-English Summary
This meta-analysis evaluated 20 randomized clinical trials of Huperzine A for Alzheimer's disease, making it the most comprehensive review of this compound. Studies used doses of 200-400mcg daily over 8-24 weeks.
Huperzine A significantly improved cognitive function (MMSE scores), activities of daily living, and global clinical assessment compared to placebo. Effect sizes were clinically meaningful and comparable to pharmaceutical cholinesterase inhibitors.
Huperzine A is a highly selective, reversible acetylcholinesterase inhibitor derived from the Chinese club moss Huperzia serrata. It increases acetylcholine availability more selectively than donepezil with fewer side effects. Huperzine A also has neuroprotective effects through NMDA receptor modulation and antioxidant activity. The compound has been used clinically in China for Alzheimer's treatment since the 1990s.